Photographs of various people working with EDRN.
Dean E. Brenner, M.D.
2150 Cancer and Geriatrics Center
University of Michigan Medical Center
1500 E. Hospital Drive
Ann Arbor, MI 48109-0930
Tel: +1 (734)647-1417
Fax: +1 (734)647-9817
Michael A. Tainsky, Ph.D.
Director, Program in Molecular Biology and Human Genetics
Karmanos Cancer Institute
Wayne State University
110 East Warren Avenue
Detroit, MI 48201
PHONE: 313-833-0715 ext. 2641
University of Michigan
Department of Pathology
M5226 Med Sci I
1301 Catherine Road
Ann Arbor, MI 48109-0602
Ph: (734) 647-8153
Fx: (734) 936-7361
Photograph of Dr Samir Hanash
Paul Engstrom, Fox Chase Cancer Center
David Fishman, Gynecologic Oncology
New York University School of Medicine
550 First Avenue NBV 9N20
New York, NY 10016
Jeffrey Marks at Duke University
Associate Professor of Surgery-Urology, Harvard Medical School
Director, Prostate Care Center
Beth Israel-Deaconess Medical Center
330 Brookline Ave
Boston, MA 02215
David Chia at UCLA.
Anna E. Lokshin, PhD
Assistant Professor of Medicine
University of Pittsburgh
University of Pittsburgh Cancer Institute
Luminex Core Facility
Hillman Cancer Center
5117 Centre Ave.
Pittsburgh, PA 15213
Virginia Prostate Center
Eastern Virginia Medical School
It's Dr Alvin Liu. A team photo is also available.
Stephen J. Meltzer
Professor of Medicine (Gastroenterology), Pathology, and Pharmacology
Staff Physician, Baltimore VA Maryland Health Care Systems
Director, GI Cancer Program
University of Maryland School of Medicine
22 S. Greene St., Rm. N3W62
Baltimore, MD 21201
"See the photograph on the NYU web site. Yours, Dr. Rom."
Dr Sanford Stass
Dr Sanford Stass of Univ of Maryland.
Update: Pre-application webinar information now available.
The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.
The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.
The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.